Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$723.12K-$723.12KN/M vs Q2 2022 EPS Diluted-$0.67-$0.67N/M vs Q2 2022 Operating Income-$574,009N/M Operating Cash Flowderived-$328,694N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end